Klin Farmakol Farm. 2014;28(3):117-119

News in contemporary management of acute coronary syndromes

Milan Hromádka1, Richard Rokyta1, David Suchý2
1 Kardiologické oddělení FN a LFUK Plzeň, Komplexní kardiovaskulární centrum FN Plzeň
2 Oddělení klinické farmakologie FN Plzeň

The inhibition of platelet receptor P2Y12 is considered to be a basic step in the treatment of patients with acute coronary syndromes (ACS).

Clopidogrel that has been widely used to date is currently being replaced with new antiplatelet drugs prasugrel and ticagrelor with a more

rapid onset of therapeutic effect and more expressed antiplatelet activity. According to the recent guidelines of the European Society

of Cardiology for the management of ACS patients with and without ST segment elevations, these drugs have a higher class of recommendation

than clopidogrel. The results of clinical trials confirmed a significant reduction in ischemic complications in ACS patients.

Keywords: STEMI, non-STEMI, prasugrel, ticagrelor, clopidogrel

Published: November 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hromádka M, Rokyta R, Suchý D. News in contemporary management of acute coronary syndromes. Klin Farmakol Farm. 2014;28(3):117-119.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský P, Kala P, Rokyta R. Souhrn Doporučených postupů ESC pro diagnostiku a léčbu pacientů s akutním infarktem myokardu s elevacemi úseku ST z roku 2012. Cor et Vasa 2012; e273-e289. Go to original source...
    2. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patiens presenting with ST-segment elevation. European Heart Journal 2012; 2569-2619.
    3. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patiens - RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-1606. Go to original source... Go to PubMed...
    4. Hamm CW, Bassand JP, S. Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patiens presenting without persistent ST-segment elevation, European Heart Journal 2011; 2999-3054.
    5. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013; 369: 999-1010. Go to original source... Go to PubMed...
    6. Mehta RS, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7). Lancet 2010; 1233-1243. Go to original source... Go to PubMed...
    7. Montalescot G, Wiviott SD, Braunwald E. Prasugrel compared with clopidogrel in patiens undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38). Lancet 2009; 373: 723-731. Go to original source... Go to PubMed...
    8. Cannon CP, Harrington RA, James S. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-293. Go to original source... Go to PubMed...
    9. James SK, Storey RF, Khurmi NS. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and history of stroke or transient ischemic attack. Circulation 2012; 125: 2914-2921. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.